BioHarmony consists of a centralized and standardized data format for preclinical, clinical, and postapproval sources, the company said. Users can export the data at any time in both computer- and human-readable formats. The database updates regularly and new feeds are available on demand, according to the firm.

Information regarding top revenue-generating drugs and potential repurposed COVID-19 drugs is available via online subscription in the BioHarmony content store. Each report contains drug, target, clinical trial, variant, safety, financial, and commercial information as well as drug indications and trends.

Swiss health data network fuels personalized medicine with data-sharing model
A nationwide data network has been built in Switzerland to support the exchange and reuse of health-related data produced in biomedical and clinical research...

AMRA adds UK Biobank images to database
Swedish image analysis software developer AMRA Medical has added additional participants from the UK Biobank study to its imaging database on body composition...

Validating drug repurposing workflows may help identify new COVID-19 treatments
A research team has strengthened COVID-19 drug repurposing workflows through independent in vitro validation followed by clinical pharmacology data assessments,...

Certara launches COVID-19 clinical database
Centara has launched the COVID-19 Clinical Outcomes database, which provides information on the results of clinical trials and observational studies on...

Beacon releases new clinical trial database
Beacon Targeted Therapies has released a new clinical trial and drug database called Beacon Oncolytic Viruses.